As CF treatment duration extends, registry-based analyses will need to track pathogen-specific trends and long-term disease ...

NewCo’ licensing of clinical candidates is allowing Chinese biotechs to offload costs while expanding profits on a global ...

China’s National Medical Products Administration (NMPA) has granted approval for four-weekly intravenous (IV) maintenance ...

Oral liquid drugs play a vital role for patients who have difficulty swallowing tablets and for those requiring personalised dosing.

Johnson & Johnson's Tremfya is the first IL-23 inhibitor to gain FDA approval in a paediatric population for plaque psoriasis ...

Genmab has signed an agreement to buy all shares of Merus at $97 per share, in an all-cash transaction valued at $8bn.

The US FDA has expanded the approval of Regeneron Pharmaceuticals' fully human monoclonal antibody, Evkeeza (evinacumab-dgnb).

Amgen has revealed a significant investment plan, earmarking $650m to enhance its manufacturing operations in the US.

After demonstrating that its gene therapy can slash Huntington's disease progression by 75%, Uniqure will now file for AMT-130's approval.

More than two-thirds – 67% - of first responders organisations have deployed new cybersecurity protections in the last 12 ...

Mérieux Equity Partners has outlined its approach to investing in Lithuania and wider Europe, highlighting a particular focus ...

Evaxion’s preclinical asset targets an unknown infectious disease in which there are no other vaccines available.